Medicine and Dentistry
Soft Tissue Sarcoma
100%
Doxorubicin
76%
Gastrointestinal Stromal Tumor
65%
Neoplasm
55%
Sarcoma
51%
Overall Survival
30%
Disease
29%
Leiomyosarcoma
24%
Quality of Life
24%
Recurrent Disease
23%
Clinical Trial
22%
Systematic Review
21%
Neck
21%
Tumor Infiltrating Lymphocyte
21%
Gemcitabine
21%
Prognostic Factor
19%
Radiation Therapy
15%
Placebo
14%
T Cell
14%
Cardiotoxicity
13%
Olaratumab
13%
Meta-Analysis
13%
Hazard Ratio
13%
Cancer Surgery
12%
Anthracycline
12%
In Vitro
12%
Surgery
12%
Oncology
12%
Specific Tumor
12%
Cell Therapy
12%
Cancer Therapy
12%
Imatinib
11%
Randomized Controlled Trial
11%
Malignant Neoplasm
11%
Brain Tumor
10%
Kidney Transplantation
10%
Eribulin
10%
Hemodialysis
10%
Merkel Cell Carcinoma
10%
Gynecological Oncology
10%
Rhabdomyosarcoma
10%
Docetaxel
10%
Kaposi Sarcoma
10%
CD8 Antigen
10%
Evofosfamide
10%
Ifosfamide
10%
Paclitaxel
10%
Arm
10%
Treatment Planning
10%
Nuclear Magnetic Resonance
10%
Keyphrases
Doxorubicin
76%
Gastrointestinal Stromal Tumor
64%
Soft Tissue Sarcoma
58%
Sarcoma
37%
Metastatic Soft Tissue Sarcoma
37%
Denmark
29%
Chemotherapy
25%
Phase II Trial
25%
Phase III Clinical Trial
22%
Head-and-neck
21%
Prognostic Value
21%
Gemcitabine
21%
Tumor-infiltrating Lymphocytes
21%
Plasma Concentration
20%
Overall Survival
20%
Advanced or Metastatic
18%
Leiomyosarcoma
17%
Patient Characteristics
16%
Phase I Trial
16%
Tumor
15%
Metastatic Gastrointestinal Stromal Tumor
14%
Advanced Gastrointestinal Stromal Tumor
14%
Cardiotoxicity
14%
Prognostic Factors
14%
Quality of Life
14%
Hazard Ratio
14%
5-year Survival
14%
Advanced Soft Tissue Sarcoma
13%
Tumor Resection
13%
Randomized Phase III Trial
13%
Olaratumab
13%
Placebo
13%
Meta-analysis
13%
Systematic Meta-analysis
13%
Improved Survival
13%
Multidisciplinary Approach
12%
Positron Emission Tomography
12%
Programmed Death-ligand 1 (PD-L1)
12%
Adoptive Cell Therapy
12%
Confidence Interval
12%
Metastatic Sarcoma
12%
Solid Tumors
12%
Oncological Treatment
12%
Log-rank Test
12%
Anthracyclines
11%
Locally Advanced Unresectable
11%
LTX-315
10%
Eribulin
10%
ABO-incompatible Kidney Transplantation
10%
Water Emissions
10%
Pharmacology, Toxicology and Pharmaceutical Science
Doxorubicin
76%
Soft Tissue Sarcoma
56%
Gastrointestinal Stromal Tumor
54%
Sarcoma
29%
Chemotherapy
24%
Leiomyosarcoma
24%
Disease
23%
Clinical Trial
22%
Gemcitabine
21%
Overall Survival
19%
Solid Malignant Neoplasm
16%
Placebo
14%
Cardiotoxicity
13%
Olaratumab
13%
Anthracycline
12%
Recurrent Disease
11%
Programmed Death 1 Receptor
10%
Pazopanib
10%
Merkel Cell Carcinoma
10%
Eribulin
10%
Evofosfamide
10%
Phase II Trials
10%
Docetaxel
10%
Programmed Death 1 Ligand 1
10%
Sorafenib
10%
Circulating Tumor DNA
10%
Idarubicin
10%
Trabectedin
10%
Sulofenur
10%
Belinostat
10%
Advanced Cancer
10%
Hemodialysis
10%
Heart Failure
10%
Dacarbazine
10%
Randomized Clinical Trial
10%
Ifosfamide
10%
Paclitaxel
10%
Kaposi Sarcoma
10%
Hyponatremia
10%
Progression Free Survival
10%
Imatinib
7%
Sunitinib
7%
Platelet Derived Growth Factor Receptor
6%
Malignant Neoplasm
6%
Adverse Event
5%
Phase I Trials
5%
Carcinoembryonic Antigen
5%
Glucose Transporter 1
5%
Remission
5%